The effect of silica nanoparticles on the immunogenicity of plant-based recombinant COE protein of porcine epidemic diarrhea virus in mice

1. Wang D, Fang L, Xiao S (2016) Porcine epidemic diarrhea in China. Virus Res 226:7. https://doi.org/10.1016/j.virusres.2016.05.02610.1016/j.virusres.2016.05.026 ↗

2. Sergeev OV (2009) Porcine epidemic diarrhea. Vopr Virusol 54(4).

3. Song D, Moon H, Kang B (2015) Porcine epidemic diarrhea: a review of current epidemiology and available vaccines. Clin Exp Vaccine Res 4:166. https://doi.org/10.7774/cevr.2015.4.2.16610.7774/cevr.2015.4.2.166 ↗

4. Diep NV, Sueyoshi M, Izzati U, Fuke N, Teh APP, Lan NT, Yamaguchi R (2018) Appearance of US-like porcine epidemic diarrhoea virus (PEDV) strains before US outbreaks and genetic heterogeneity of PEDVs collected in Northern Vietnam during 2012–2015. Transbound Emerg Dis 65:e83–e93. https://doi.org/10.1111/tbed.1268110.1111/tbed.12681 ↗

5. Than VT, Choe SE, Vu TTH, Do TD, Nguyen TL, Bui TTN, Mai TN, Cha RM, Song D, An DJ, Le VP (2020) Genetic characterization of the spike gene of porcine epidemic diarrhea viruses (PEDVs) circulating in Vietnam from 2015 to 2016. Vet Med Sci 6:535. https://doi.org/10.1002/vms3.25610.1002/vms3.256 ↗

6. Chang SH, Bae JL, Kang TJ, Kim J, Chung GH, Lim CW, Laude H, Yang MS, Jang YS (2002) Identification of the epitope region capable of inducing neutralizing antibodies against the porcine epidemic diarrhea virus. Mol Cells 14:295–29910.1016/S1016-8478(23)15106-5 ↗

7. Chang CY, Cheng IC, Chang YC, Tsai PS, Lai SY, Huang YL, Jeng CR, Pang VF, Chang HW (2019) Identification of neutralizing monoclonal antibodies targeting novel conformational epitopes of the porcine epidemic diarrhoea virus spike protein. Sci Rep 9:2529. https://doi.org/10.1038/s41598-019-39844-510.1038/s41598-019-39844-5 ↗

8. Hsueh FC, Lin CN, Chiou HY, Chia MY, Chiou MT, Haga T, Kao CF, Chang YC, Chang CY, Jeng CR, Chang HW (2020) Updated phylogenetic analysis of the spike gene and identification of a novel recombinant porcine epidemic diarrhoea virus strain in Taiwan. Transbound Emerg Dis 67:417. https://doi.org/10.1111/tbed.1336510.1111/tbed.13365 ↗

9. Tien NQ, Yang MS, Jang YS, Kwon TH, Reljic R, Kim MY (2021) Systemic and oral immunogenicity of porcine epidemic diarrhea virus antigen fused to poly Fc of immunoglobulin G and expressed in ΔXT/FT Nicotiana benthamiana plants. Front Pharmacol 12. https://doi.org/10.3389/fphar.2021.65306410.3389/fphar.2021.653064 ↗

10. Oszvald M, Kang TJ, Tomosközi S, Tamás C, Tamás L, Kim TG, Yang MS (2007) Expression of a synthetic neutralizing epitope of porcine epidemic diarrhea virus fused with synthetic B subunit of Escherichia coli heat labile enterotoxin in rice endosperm. Mol Biotechnol 35:215–223. https://doi.org/10.1007/BF0268600710.1007/BF02686007 ↗

11. Huy NX, Kim SH, Yang MS, Kim TG (2012) Immunogenicity of a neutralizing epitope from porcine epidemic diarrhea virus: M cell targeting ligand fusion protein expressed in transgenic rice calli. Plant Cell Rep 31:1933–1942. https://doi.org/10.1007/s00299-012-1306-010.1007/s00299-012-1306-0 ↗

12. Ho TT, Nguyen GT, Pham NB, Le VP, Trinh TBN, Vu TH, Phan HT, Conrad U, Chu HH (2020) Plant-derived trimeric CO-26K-equivalent epitope induced neutralizing antibodies against porcine epidemic diarrhea virus. Front Immunol 11:2152. https://doi.org/10.3389/fimmu.2020.0215210.3389/fimmu.2020.02152 ↗

13. Arndt K, Fink GR (1986) GCN4 protein, a positive transcription factor in yeast, binds general control promoters at all 5′ TGACTC 3′ sequences. Proc Natl Acad Sci USA 83:8516–8520. https://doi.org/10.1073/pnas.83.22.851610.1073/pnas.83.22.8516 ↗

14. Harbury PB, Zhang T, Kim PS, Alber T (1993) A switch between two, three, and four stranded coiled coils in GCN4 leucine zipper mutants. Science 262:1401–1407. https://doi.org/10.1126/science.824877910.1126/science.8248779 ↗

15. Ho TT, Trinh VT, Tran HX, Le PTT, Nguyen TT, Hoang HTT, Pham MD, Conrad U, Pham NB, Chu HH (2022) The immunogenicity of plant-based COE-GCN4pII protein in pigs against the highly virulent porcine epidemic diarrhea virus strain from genotype 2. Front Vet Sci 9. https://doi.org/10.3389/fvets.2022.94039510.3389/fvets.2022.940395 ↗

16. Jennings GT, Bachmann MF (2008) The coming of age of virus-like particle vaccines. Biol Chem 389:521. https://doi.org/10.1515/bc.2008.06410.1515/bc.2008.064 ↗

17. Ludwig C, Wagner R (2007) Virus-like particles—universal molecular toolboxes. Curr Opin Biotechnol 18:537. https://doi.org/10.1016/j.copbio.2007.10.01310.1016/j.copbio.2007.10.013 ↗

18. Asbach B, Wagner R (2017) Particle-based delivery of the HIV envelope protein. Curr Opin HIV AIDS 12:265. https://doi.org/10.1097/COH.000000000000036610.1097/COH.0000000000000366 ↗

19. Anselmo AC, Mitragotri S (2019) Nanoparticles in the clinic: an update. Bioeng Transl Med 4. https://doi.org/10.1002/btm2.1014310.1002/btm2.10143 ↗

20. Barbey C, Su J, Billmeier M, Stefan N, Bester R, Carnell G, Temperton N, Heeney J, Protzer U, Breunig M, Wagner R, Peterhoff D (2023) Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice. Eur J Pharm Biopharm 192:41. https://doi.org/10.1016/j.ejpb.2023.09.01510.1016/j.ejpb.2023.09.015 ↗

21. Metz SW, Tian S, Hoekstra G, Yi X, Stone M, Horvath K, Miley MJ, DeSimone J, Luft CJ, de Silva AM (2016) Precisely molded nanoparticle displaying DENV-E proteins induces robust serotype-specific neutralizing antibody responses. PLoS Negl Trop Dis 10. https://doi.org/10.1371/journal.pntd.000507110.1371/journal.pntd.0005071 ↗

22. Zhao Q, Li S, Yu H, Xia N, Modis Y (2013) Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol 31:654. https://doi.org/10.1016/j.tibtech.2013.09.00210.1016/j.tibtech.2013.09.002 ↗

23. Marcandalli J, Fiala B, Ols S, Perotti M, de van der Schueren W, Snijder J, Hodge E, Benhaim M, Ravichandran R, Carter L, Sheffler W, Brunner L, Lawrenz M, Dubois P, Lanzavecchia A, Sallusto F, Lee KK, Veesler D, Correnti CE, Stewart LJ, Baker D, Loré K, Perez L, King NP, (2019) Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell 176:1420. https://doi.org/10.1016/j.cell.2019.01.04610.1016/j.cell.2019.01.046 ↗

24. Boyoglu-Barnum S, Ellis D, Gillespie RA, Hutchinson GB, Park YJ, Moin SM, Acton OJ, Ravichandran R, Murphy M, Pettie D, Matheson N, Carter L, Creanga A, Watson MJ, Kephart S, Ataca S, Vaile JR, Ueda G, Crank MC, Stewart L, Lee KK, Guttman M, Baker D, Mascola JR, Veesler D, Graham BS, King NP, Kanekiyo K (2021) Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature 592:623–628. https://doi.org/10.1038/s41586-021-03365-x10.1038/s41586-021-03365-x ↗

25. Brinkkemper M, Sliepen K (2019) Nanoparticle vaccines for inducing HIV-1 neutralizing antibodies. Vaccines (Basel) 7:76. https://doi.org/10.3390/vaccines703007610.3390/vaccines7030076 ↗

26. Bruun TUJ, Andersson A-MC, Draper SJ, Howarth M (2018) Engineering a rugged nanoscaffold to enhance plug-and-display vaccination. ACS Nano 12:8855–8866. https://doi.org/10.1021/acsnano.8b0280510.1021/acsnano.8b02805 ↗

27. Shirai S, Kawai A, Shibuya M, Munakata L, Omata D, Suzuki R, Yoshioka Y (2020) Lipid nanoparticle acts as a potential adjuvant for influenza split vaccine without inducing inflammatory responses. Vaccines (Basel) 8:433. https://doi.org/10.3390/vaccines803043310.3390/vaccines8030433 ↗

28. Chattopadhyay S, Chen JY, Chen HW, Hu CJ (2017) Nanoparticle vaccines adopting virus-like features for enhanced immune potentiation. Nanotheranostics 1:244–260. https://doi.org/10.7150/ntno.1979610.7150/ntno.19796 ↗

29. Thalhauser S, Peterhoff D, Wagner R, Breunig M (2020) Critical design criteria for engineering a nanoparticulate HIV-1 vaccine. J Control Release 317:322. https://doi.org/10.1016/j.jconrel.2019.11.03510.1016/j.jconrel.2019.11.035 ↗

30. Zhang W, Wang L, Liu Y, Chen X, Liu Q, Jia J, Yang T, Qiu S, Ma G (2014) Immune responses to vaccines involving a combined antigen–nanoparticle mixture and nanoparticle-encapsulated antigen formulation. Biomaterials 35:6086. https://doi.org/10.1016/j.biomaterials.2014.04.02210.1016/j.biomaterials.2014.04.022 ↗

31. Anselmo AC, Mitragotri S (2021) Nanoparticles in the clinic: an update post COVID-19 vaccines. Bioeng Transl Med 6. https://doi.org/10.1002/btm2.1024610.1002/btm2.10246 ↗

32. Nguyen B, Tolia NH (2021) Protein-based antigen presentation platforms for nanoparticle vaccines. NPJ Vaccines 6:70. https://doi.org/10.1038/s41541-021-00330-710.1038/s41541-021-00330-7 ↗

33. Rudra JS, Tian YF, Jung JP, Collier JH (2010) A self-assembling peptide acting as an immune adjuvant. Proc Natl Acad Sci USA 107:622–627. https://doi.org/10.1073/pnas.091212410710.1073/pnas.0912124107 ↗

34. Swartz MA, Hirosue S, Hubbell JA (2012) Engineering approaches to immunotherapy. Sci Transl Med 4:148rv9. https://doi.org/10.1126/scitranslmed.300376310.1126/scitranslmed.3003763 ↗

35. Liu Y, Yao Y, Fu J, Hu W, Feng J, Wan J, Yu C (2021) Large-scale synthesis of fractal silica nanoparticles: understanding the impact of solvents. Microporous Mesoporous Mater 316. https://doi.org/10.1016/j.micromeso.2021.11097610.1016/j.micromeso.2021.110976 ↗

36. Anselmo AC, Mitragotri S (2015) A review of clinical translation of inorganic nanoparticles. AAPS J 17:1041. https://doi.org/10.1208/s12248-015-9780-210.1208/s12248-015-9780-2 ↗

37. Fu J, Jiao J, Ban W, Kong Y, Gu Z, Song H, Huang X, Yang Y, Yu C (2021) Large scale synthesis of self-assembled shuttlecock-shaped silica nanoparticles with minimized drag as advanced catalytic nanomotors. Chem Eng J 417. https://doi.org/10.1016/j.cej.2020.12797110.1016/j.cej.2020.127971 ↗

38. Zhao X, Bagwe RP, Tan W (2004) Development of organic-dye-doped silica nanoparticles in a reverse microemulsion. Adv Mater 16:173. https://doi.org/10.1002/adma.20030562210.1002/adma.200305622 ↗

39. Zhelev Z, Ohba H, Bakalova R (2006) Single quantum dot-micelles coated with silica shell as potentially non-cytotoxic fluorescent cell tracers. J Am Chem Soc 128:6324. https://doi.org/10.1021/ja061137d10.1021/ja061137d ↗

40. Chaudhary Z, Khan GM, Abeer MM, Pujara N, Tse BW-C, McGuckin MA, Popat A, Kumeria T (2019) Efficient photoacoustic imaging using indocyanine green (ICG) loaded functionalized mesoporous silica nanoparticles. Biomater Sci 7:5002. https://doi.org/10.1039/c9bm00822e10.1039/c9bm00822e ↗

41. Abeer AM, Meka AK, Pujara N, Kumeria T, Strounina E, Nunes R, Costa A, Sarmento B, Hasnain SZ, Ross BP, Popat A (2019) Rationally designed dendritic silica nanoparticles for oral delivery of exenatide. Pharmaceutics 11:418. https://doi.org/10.3390/pharmaceutics1108041810.3390/pharmaceutics11080418 ↗

42. Raza A, Sime FB, Cabot PJ, Roberts JA, Falconer JR, Kumeria T, Popat A (2021) Liquid CO₂ formulated mesoporous silica nanoparticles for pH-responsive oral delivery of meropenem. ACS Biomater Sci Eng 7:1836–1847. https://doi.org/10.1021/acsbiomaterials.0c0128410.1021/acsbiomaterials.0c01284 ↗

43. Ye L, Liang C, He J, Ou J, Wu Q (2018) Facile preparation of ordered macroporous carboxyl group functionalized polymer SiO₂ composites and their adsorption performance towards proteins. J Inorg Organomet Polym 28:1011. https://doi.org/10.1007/s10904-018-0789-810.1007/s10904-018-0789-8 ↗

44. Santra S, Dutta D, Moudgil BM (2005) Functional dye-doped silica nanoparticles for bioimaging, diagnostics and therapeutics. Food Bioprod Process 83:136–143. https://doi.org/10.1205/fbp.0440010.1205/fbp.04400 ↗

45. Bagwe RP, Hilliard LR, Tan W (2006) Surface modification of silica nanoparticles to reduce aggregation and nonspecific binding. Langmuir 22:4357. https://doi.org/10.1021/la052797j10.1021/la052797j ↗

46. Hilliard LR, Zhao X, Tan W (2002) Immobilization of oligonucleotides onto silica nanoparticles for DNA hybridization studies. Anal Chim Acta 470:5110.1016/S0003-2670(02)00538-X ↗

47. Nguyen TT, Nguyen HN, Nghiem THL, Do XH, To TT, Do XP, Do DL, Nguyen HG, Nguyen HM, Nguyen ND, Luu MQ, Nguyen TN, Nguyen TBN, Nguyen VT, Pham VT, Than UTT, Hoang TMN (2024) High biocompatible FITC-conjugated silica nanoparticles for cell labeling in both in vitro and in vivo models. Sci Rep 14:6969. https://doi.org/10.1038/s41598-024-55600-w10.1038/s41598-024-55600-w ↗

48. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FT, de Beer TAP, Rempfer C, Bordoli L, Lepore R, Schwede T (2018) SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 46:W296. https://doi.org/10.1093/nar/gky42710.1093/nar/gky427 ↗

49. Waterhouse AM, Studer G, Robin X, Bienert S, Tauriello G, Schwede T (2024) The structure assessment web server: for proteins, complexes and more. Nucleic Acids Res 52:W318. https://doi.org/10.1093/nar/gkae27010.1093/nar/gkae270 ↗

50. Bienert S, Waterhouse A, de Beer TAP, Tauriello G, Studer G, Bordoli L, Schwede T (2017) The SWISS-MODEL Repository—new features and functionality. Nucleic Acids Res 45:D313–D319. https://doi.org/10.1093/nar/gkw113210.1093/nar/gkw1132 ↗

51. Guex N, Peitsch MC, Schwede T (2009) Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective. Electrophoresis 30:S162–S173. https://doi.org/10.1002/elps.20090014010.1002/elps.200900140 ↗

52. Kusanagi K, Kuwahara H, Katoh T, Nunoya T, Ishikawa Y, Samejima T, Tajima M (1992) Isolation and serial propagation of porcine epidemic diarrhea virus in cell cultures and partial characterization of the isolate. J Vet Med Sci 54:313. https://doi.org/10.1292/jvms.54.31310.1292/jvms.54.313 ↗

53. Mody KT, Popat A, Mahony D, Cavallaro AS, Yu C, Mitter N (2013) Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery. Nanoscale 5:5167–5179. https://doi.org/10.1039/c3nr00357d10.1039/c3nr00357d ↗

54. Carvalho LV, Ruiz RC, Scaramuzzi K, Marengo EB, Matos JR, Tambourgi DV, Fantini MC, Sant’Anna OA (2010) Immunological parameters related to the adjuvant effect of the ordered mesoporous silica SBA-15. Vaccine 28:7829–7836. https://doi.org/10.1016/j.vaccine.2010.09.08710.1016/j.vaccine.2010.09.087 ↗

55. Montalvo-Quirós S, Vallet-Regí M, Palacios A, Anguita J, Prados-Rosales RC, González B, Luque-Garcia JL (2020) Mesoporous silica nanoparticles as a potential platform for vaccine development against tuberculosis. Pharmaceutics 12:1218. https://doi.org/10.3390/pharmaceutics1212121810.3390/pharmaceutics12121218 ↗

56. Liu T, Liu H, Fu C, Li L, Chen D, Zhang Y, Tang F (2013) Silica nanorattle with enhanced protein loading: a potential vaccine adjuvant. J Colloid Interface Sci 400:168. https://doi.org/10.1016/j.jcis.2013.03.00510.1016/j.jcis.2013.03.005 ↗

57. Skrastina D, Petrovskis I, Lieknina I, Bogans J, Renhofa R, Ose V, Dishlers A, Dekhtyar Y, Pumpens P (2014) Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles. PLoS ONE 9. https://doi.org/10.1371/journal.pone.011400610.1371/journal.pone.0114006 ↗

58. Oliveira DCDP, De Barros ALB, Belardi RM, De Goes AM, De Oliveira BKD, Soares DCF (2016) Mesoporous silica nanoparticles as a potential vaccine adjuvant against Schistosoma mansoni. J Drug Deliv Sci Technol 35:234–240. https://doi.org/10.1016/j.jddst.2016.07.00210.1016/j.jddst.2016.07.002 ↗

59. Lu Y, Yang Y, Gu Z, Zhang J, Song H, Xiang G, Yu C (2018) Glutathione-depletion mesoporous organosilica nanoparticles as a self-adjuvant and co-delivery platform for enhanced cancer immunotherapy. Biomaterials 175:82. https://doi.org/10.1016/j.biomaterials.2018.05.02510.1016/j.biomaterials.2018.05.025 ↗

60. Du G, Woythe L, van der Maaden K, Leone M, Romeijn S, Kros A, Kersten G, Jiskoot W, Bouwstra JA (2018) Coated and hollow microneedle-mediated intradermal immunization in mice with diphtheria toxoid loaded mesoporous silica nanoparticles. Pharm Res 35:189. https://doi.org/10.1007/s11095-018-2476-410.1007/s11095-018-2476-4 ↗

61. Van Horn JD, Huang H (2006) Uranium(VI) bio coordination chemistry from biochemical, solution and protein structural data. Coord Chem Rev 250:765–775. https://doi.org/10.1016/j.ccr.2005.09.01010.1016/j.ccr.2005.09.010 ↗

62. Dong Y, Gao J, Pei M, Wang X, Zhang C, Du Y, Jiang Y (2020) Antigen-conjugated silica solid sphere as nanovaccine for cancer immunotherapy. Int J Nanomedicine 15:2685–2696. https://doi.org/10.2147/IJN.S24246310.2147/IJN.S242463 ↗

63. Wang Y, Liu S, Li B, Sun X, Pan Q, Zheng Y, Liu J, Zhao Y, Wang J, Liu L, Du E (2024) A novel CpG ODN compound adjuvant enhances immune response to spike subunit vaccines of porcine epidemic diarrhea virus. Front Immunol 15:1336239. https://doi.org/10.3389/fimmu.2024.133623910.3389/fimmu.2024.1336239 ↗

64. Cheng S, Pal S, Bettahi I, Oxford KL, Barry PA, de la Maza LM (2011) Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F native major outer membrane protein in a nonhuman primate model. Vaccine 29:3456–3464. https://doi.org/10.1016/j.vaccine.2011.02.05710.1016/j.vaccine.2011.02.057 ↗

65. Hammerschmidt SI, Friedrichsen M, Boelter J, Lyszkiewicz M, Kremmer E, Pabst O et al (2011) Retinoic acid induces homing of protective T and B cells to the gut after subcutaneous immunization in mice. J Clin Invest 121:3051–3061. https://doi.org/10.1172/JCI4426210.1172/JCI44262 ↗

66. Yang GB, Wang Y, Babaahmady K, Schøller J, Rahman D, Bunnik E, Spallek R, Zong CM, Duan JZ, Qin C, Jiang H, Singh M, Vaughan R, Bergmeier LA, Schuitemaker H, Shao Y, Lehner T (2012) Immunization with recombinant macaque major histocompatibility complex class I and II and human immunodeficiency virus gp140 inhibits simian human immunodeficiency virus infection in macaques. J Gen Virol 93:1506–1518. https://doi.org/10.1099/vir.0.041061-010.1099/vir.0.041061-0 ↗

67. de Arriba ML, Carvajal A, Pozo J, Rubio P (2002) Mucosal and systemic isotype-specific antibody responses and protection in conventional pigs exposed to virulent or attenuated porcine epidemic diarrhoea virus. Vet Immunol Immunopathol 85(1–2):85–97. https://doi.org/10.1016/s0165-2427(01)00417-210.1016/s0165-2427(01)00417-2 ↗

68. Annamalai T, Lin CM, Gao X, Liu X, Lu Z, Saif LJ et al (2017) Cross-protective immune responses in nursing piglets infected with a US spike-insertion deletion porcine epidemic diarrhea virus strain and challenged with an original US PEDV strain. Vet Res 48(1):61. https://doi.org/10.1186/s13567-017-0469-710.1186/s13567-017-0469-7 ↗

69. Krishna VD, Kim Y, Yang M, Vannucci F, Molitor T, Torremorell M, Cheeran MC (2020) Immune responses to porcine epidemic diarrhea virus (PEDV) in swine and protection against subsequent infection. PLoS ONE 15(4). https://doi.org/10.1371/journal.pone.023172310.1371/journal.pone.0231723 ↗

70. Zinkernagel RM (2001) Maternal antibodies, childhood infections, and autoimmune diseases. N Engl J Med 345:1331–1335. https://doi.org/10.1056/NEJMra01249310.1056/NEJMra012493 ↗

71. Jang G, Lee D, Shin S, Lim J, Won H, Eo Y, Kim CH, Lee C (2023) Porcine epidemic diarrhea virus: an updated overview of virus epidemiology, vaccines, and control strategies in South Korea. J Vet Sci 24. https://doi.org/10.4142/jvs.2309010.4142/jvs.23090 ↗

72. Duong BTT, Thao PTP, Hoa NT et al (2022) Molecular analysis reveals a distinct subgenogroup of porcine epidemic diarrhea virus in northern Vietnam in 2018–2019. Arch Virol 167:2337–2346. https://doi.org/10.1007/s00705-022-05580-x10.1007/s00705-022-05580-x ↗

73. Zhao Y, Fan B, Song X, Gao J, Guo R, Yi C, He Z, Hu H, Jiang J, Zhao L, Zhong T, Li B (2024) PEDV spike protein expressing mRNA vaccine protects piglets against PEDV challenge. mBio 15:e0295823. https://doi.org/10.1128/mbio.02958-23.10.1128/mbio.02958-23 ↗

74. Murtaza A, Hoa NT, Dieu Huong D, Afzal H, Tariq MH, Cheng LT, Chung YC (2024) Advancing PEDV vaccination: comparison between inactivated and flagellin N terminus adjuvanted subunit vaccines. Vaccines 12:139. https://doi.org/10.3390/vaccines1202013910.3390/vaccines12020139 ↗

75. Song X, Li Y, Wang C, Zhao Y, Yang S, Guo R, Hu M, Sun M, Zhang G, Li Y, Wang Y, Liu S, Shen Y, Li C, Zhang X, Li J, Fan B, Li B (2024) Efficacy evaluation of a bivalent subunit vaccine against epidemic PEDV heterologous strains with low cross protection. J Virol 98:e01309-e1324. https://doi.org/10.1128/JVI.01309-2410.1128/JVI.01309-24 ↗

76. Meng F, Ren Y, Suo S, Sun X, Li X, Li P, Yang W, Li G, Li L, Schwegmann-Wessels C, Herrler G, Ren X (2013) Evaluation on the efficacy and immunogenicity of recombinant DNA plasmids expressing spike genes from porcine transmissible gastroenteritis virus and porcine epidemic diarrhea virus. PLoS ONE 8(3). https://doi.org/10.1371/journal.pone.005746810.1371/journal.pone.0057468 ↗

77. Navarro E, Mainau E, de Miguel R, Temple D, Salas M, Manteca X (2021) Oral Meloxicam administration in sows at farrowing and its effects on piglet immunity transfer and growth. Front Vet Sci 8. https://doi.org/10.3389/fvets.2021.57425010.3389/fvets.2021.574250 ↗

78. Schoenborn JR, Wilson CB (2007) Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96:41–101. https://doi.org/10.1016/S0065-2776(07)96002-210.1016/S0065-2776(07)96002-2 ↗

79. Mody KT, Mahony D, Zhang J, Cavallaro AS, Zhang B, Popat A, Mahony TJ, Yu C, Mitter N (2014) Silica vesicles as nanocarriers and adjuvants for generating both antibody and T-cell mediated immune responses to bovine viral diarrhoea virus E2 protein. Biomaterials 35:9972–9983. https://doi.org/10.1016/j.biomaterials.2014.08.04410.1016/j.biomaterials.2014.08.044 ↗

80. Pavlin M, Lojk J, Strojan K, Hafner-Bratkovič I, Jerala R, Leonardi A, Križaj I, Drnovšek N, Novak S, Veranič P et al (2022) The relevance of physico-chemical properties and protein corona for evaluation of nanoparticles immunotoxicity—in vitro correlation analysis on THP-1 macrophages. Int J Mol Sci 23:6197. https://doi.org/10.3390/ijms2311619710.3390/ijms23116197 ↗

81. Chen MC, Lai KY, Ling MH, Lin CW (2018) Enhancing immunogenicity of antigens through sustained intradermal delivery using chitosan microneedles with a patch-dissolvable design. Acta Biomater 65:66–75. https://doi.org/10.1016/j.actbio.2017.11.00410.1016/j.actbio.2017.11.004 ↗